drugset
drugset / Trial / NCT03547375

Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy

NCT03547375 ↗

Phase 2 Unknown 69 enrolled Anhui Provincial Hospital
NaSingle-groupOpen-labelTreatment

Summary

To Observe and Evaluate the Efficacy and Safety of Apatinib in Patients With Advanced Ovarian Cancer After the Failure of Standard Chemotherapy

Timeline

Start
2018-06-01
Primary completion
2019-12-01
Completion
2020-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 500 mg Oral

Indications

ovarian cancer